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Abstract 
In the cases of acute leukemia we may find beside the characteristic clinical syndromes, well described in the medical literature, 
also a series of psychological modifications. These last ones are reflected heterogeneously in the specialized literature. The 
purpose of this article was to investigate in the cases of patients with acute leukemia, the variations of depression and anxiety 
during three distinct phases of chemotherapy treatment (induction, consolidation and maintenance), for both genders. The 
estimated differences were tested with the help of the covariance analysis; the number of the blast cells in the peripheral blood 
was considered a factor of covariance for depression and anxiety. The results obtained proved significant increases of depression 
and anxiety in the phase of induction and consolidation, both depression and anxiety being in relation of covariance with the 
number of blast cells. 
© 2014 The Authors. Published by Elsevier Ltd. 
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1. Introduction 
Acute leukemia represents a group of hematologic disorders during which a clonal proliferation of the immature 
blood cells (blasted) takes place at myeloid and lymphoblast levels, simultaneously with the suppression of the 
normal clones. 
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Thus leukemia expresses a myeloid insufficiency, which is clinically generating 3 syndromes: anemia, infectious 
and bleeding problems. There are two types of acute leukemia: Lymphoblastic Acute leukemia (LAL), mostly 
diagnosed at children and young adults (Jameson et al., 2005) and  Myelogenous acute leukemia (LAM), whose 
incidence rises with age (Colvin et al., 2003). These two represent approximately 10% of all types of cancer 
officially registered. At the moment there are a lot of methods for the diagnosis of the different forms of leukemia, 
which include cytomorphology, cytogenetics, fluorescence in situ hybridization (FISH), polymerase chain reaction 
(PCR), and immunophenotyping with multiparameter flow cytometry (MFC) (Bacher et al, 2009; Haferlach, 2005; 
Neubauer, 2001). For the diagnosis of LAL and LAM one of the main indicators of the diagnosis remains the 
percentage value of the blast cells that entered into the peripheral blood. 
The depression and the anxiety have been studied in cases of cancer but there are still a small number of 
researches about the way they are evolving in cases of acute leukemia. Gordjin et al. (2013) proved that sleep 
disturbance and fatigue are correlated with more symptoms of depression in cases of patients with LAL. Tomer et al. 
(2007) discovered that depression and anxiety are stronger at persons with ages under 60, but the two symptoms do 
not differentiate the persons who are going through different phases of treatment as in ”watch and wait” versus 
”active-treatment groups” in the LAL cases. Cardenal et al. (2012) identified a significantly higher level of anxiety 
at the group of patients with leukemia than at the control group. In the case of depression the researchers did not 
identify significant differences between the groups compared. 
Vybornykh et al. (2004) noticed that in those cases of patients diagnosed with leukemia, the level of depression 
was quite a notable one, but it was masked by a series of somatic symptoms. Rosales and Polly (2008) proved that 
the anxiety and the depression are significantly increasing in the first month after the patient is being diagnosed, as a 
result of the negative meaning of the word cancer/leukemia, but their intensity is decreasing afterwards, due to the 
control given by the information received by the patients about the disease. 
The purpose of this research was that of testing if there are any differences in the intensity of depression and 
anxiety during the three phases of chemotherapy treatment, but also if the gender at the patients with acute leukemia 
has an influence. Furthermore we have tested if the number of blast cells in the peripheral blood explains partially 
the variation of depression and anxiety during the phases of treatment. Thus we have tested the following 
hypothesis: H1: The level of depression at the patients with acute leukemia depends on the phase of treatment 
(induction, re-induction, consolidation) and the gender of the respondents, when the level of blast cells is being 
controlled. H2: The anxiety level at the patients with acute leukemia depends on the phase of treatment applied and 
the gender of the respondents, when the level of the blast cells is being controlled. 
2. Method 
2.1. Participants and procedure 
The sample consisted of 327 persons, who beneficiate of chemotherapy treatment after being diagnosed with 
acute leukemia (LAL or LAM). Out of them 54.7% were males. The age average was 51.16, with a standard 
deviation of 14.8 points. Depending on the phase of the disease (initial phase, relapse and remission) the patients 
were included into one of the next three groups, accordingly to the treatment phase: Induction group (N=117), 
Consolidation group (N=112) and Maintenance group (N=98). 
2.2. Measures
The level of depression was measured with the help of the scale BDI-II (Beck et al., 1996). The scale contains 21 
questions, each answer being scored on a scale value of 0 to 3. The cutoffs are: 0–13: minimal depression; 14–19: 
mild depression; 20–28: moderate depression; and 29–63: severe depression. Higher total scores indicate more 
severe depressive symptoms. For the measurement of the level of anxiety the Hamilton scale was used. The scale 
contains  14  items/  symptoms rated  from not  present  (0)  to  very  severe  (4).  A total  score  of  0-17 is  considered  to  
be mild, 18-25 mild to moderate, 26-30 moderate to severe, and 30 very severe anxiety. The percentage of the blast 
cells at the level of the peripheral blood was assessed by morphological analysis laboratory in microscopic field. 
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2.3. Data analysis 
For testing our hypothesis we used the analysis of covariance (ANCOVA). More specifically we tested if the 
phase of chemotherapy treatment (induction, re-induction and consolidation) is a factor that controls significantly 
the variation of depression and anxiety at patients with leukemia. Another factor depending on which we monitored 
the variations of the depression was the gender. Due to the fact that in the diagnosis of leukemia the percentage 
value of the blast cells that get to the peripheral blood is a clinical indicator, we have tested in the same time if this 
variable covariates depending on the intensity of the depression at patients with leukemia. 
3. Results 
In the table below we are presenting the means and standard deviations for the three groups formed on the criteria 
of  the  phases  of  the  treatment,  both  for  men  and  women.  It  may  be  noticed  that  in  both  cases  of  depression  and  
anxiety the mean values are indicating high levels compared with the theoretical levels of the scales.  






Mean Std. Deviation Mean Std. Deviation 
Induction phase 
females 40.41 4.32 43.22 6.39 
males 42.03 5.17 45.63 7.15 
Re-induction phase 
females 40.60 4.61 48.69 5.34 
males 42.54 5.87 51.32 4.43 
Consolidation phase 
females 22.91 5.46 29.04 5.99 
males 23.09 4.95 30.25 5.43 
At the level of first hypothesis, the gender factor had only a marginal effect over depression level F (1, 320) = 
3.40, p=.066, but anyway over the accepted limit. The interaction between treatment phase and gender with patients’ 
depression was also not significant F (2, 320) = .58, p>.05. For this reason we re-estimated the model without 
gender factor and correspondent interaction term. Thus, for the simplified model the covariate, percent of blast cells, 
was significantly related to the patients’ level of depression F(1, 323) = 23.73, p<.001, with  a magnitude of effect r 
=.27. There was also a significant effect of treatment phase factor on levels of depression, after controlling for the 
effect of covariate (blast cells), F(2, 323) = 42.37, p<.001. Planned contrast revealed that being in the induction 
phase significantly increase the level of depression compared to being in consolidation phase t(325)=8.01, p<.001, 
r=.41. The re-induction group scored significantly higher than consolidation group t(325)=5.62, p<.001, r=.30. 
These contrasts illustrates a moderate to large effect of treatment phase over the depression level as can be seen in 
the figure below. 
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Figure 1.Depression levels over treatment phase 
At the level of second hypothesis, both treatment phase and gender had a significant simple effect, but interaction 
was insignificant. The covariate, percent of blast cells, was significantly related to the patients’ level of depression 
F(1, 320) = 46.85, p<.001, with  a magnitude of effect r =.36.  
After controlling for the effect of covariate (blast cells), treatment phase factor had a significant effect over the 
levels of anxiety F(2, 320) = 7.67, p<.01. Planned contrast revealed that being in the induction phase significantly 
increase the level of anxiety compared to being in consolidation phase t (325) = 2.86, p<.001, r=.16. The re-
induction group scored significantly higher than consolidation group t (325) = 3.84, p<.001, r=.21. This contrast 
illustrates a small effect of treatment phase over the anxiety level as can be seen in the figure below. In this case the 
gender factor had a significant effect over anxiety level F (1, 320) = 7.08, p<.01, males being more anxious then 
females. 
Figure 2.Anxiety levels over treatment phase
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4. Discussion and conclusions 
Both the depression and the anxiety of the patients with acute leukemia vary depending on the phase of the 
disease and on the treatment applied. The depression of the patients with acute leukemia is manifesting its higher 
level in the phase of induction of the chemotherapy treatment and then in the consolidation phase, between these 
two treatment phases significant statistical differences were not observed. The highest level of anxiety of the 
patients with acute leukemia is manifested when they are passing though the consolidation phase of the 
chemotherapy treatment. This sort of configuration of the two variables is predictable taking into consideration the 
fact that the chemotherapy treatment is by definition an invasive one and it creates side effects as depression and 
anxiety symptoms.  
The increase of the number of blast cells in the peripheral blood is accompanied by the increase of the depression 
and anxiety at these patients. The mechanism behind this association is most probably also of chemical as of 
psychological nature. For instance Schiepers et al. (2005) offered an explanatory model of the way how the immune 
system through the cytokines participates to the installation of the neurochemical and neuroendocrinological 
behavioral symptoms of depression. Rosales & Polly (2008) showed that anxiety and depression at patients with 
leukemia may decrease in intensity, due to the control offered by the information received by the patients about their 
disease. The clarification of these mechanisms goes beyond the purpose of this paper, further investigations being 
necessary. 
The anxiety level varies depending on the gender, in the sense that no matter the type of treatment associated to a 
phase of the disease, the men with leukemia develop a significantly higher level of anxiety comparatively to the 
women diagnosed with leukemia. This fact proves a bigger deficit in coping resources at men with leukemia in the 
induction or consolidation phases of chemotherapy treatment. The data obtained suggest the need for 
psychotherapeutic counseling for the patients with acute leukemia especially in the phases of induction and 
consolidation of the chemotherapy treatment. 
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